NASDAQ · IKT
Healthcare · Biotechnology
$1.55
Down-$0.12 (-7.19%)
Updated Oct 31, 2026, 3:10 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IKT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IKT closed at $1.55 after 21 trading sessions, down 22.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.67 | $1.67 | $1.52 | $1.55 | 438.29K |
| Oct 29, 2026 | $1.64 | $1.695 | $1.625 | $1.67 | 852.37K |
| Oct 28, 2026 | $1.55 | $1.63 | $1.53 | $1.62 | 386.65K |
| Oct 27, 2026 | $1.53 | $1.61 | $1.495 | $1.57 | 1.19M |
| Oct 26, 2026 | $1.60 | $1.60 | $1.50 | $1.52 | 860.47K |
| Oct 23, 2026 | $1.60 | $1.65 | $1.541 | $1.59 | 408.8K |
| Oct 22, 2026 | $1.65 | $1.65 | $1.58 | $1.63 | 310.49K |
| Oct 21, 2026 | $1.71 | $1.76 | $1.64 | $1.66 | 529.01K |
| Oct 20, 2026 | $1.65 | $1.75 | $1.63 | $1.71 | 363.42K |
| Oct 19, 2026 | $1.67 | $1.72 | $1.57 | $1.645 | 1.33M |
| Oct 16, 2026 | $1.82 | $1.82 | $1.65 | $1.65 | 917.21K |
| Oct 15, 2026 | $1.80 | $1.87 | $1.795 | $1.83 | 401.75K |
| Oct 14, 2026 | $1.73 | $1.865 | $1.72 | $1.80 | 1.58M |
| Oct 13, 2026 | $1.85 | $1.875 | $1.73 | $1.76 | 1.17M |
| Oct 12, 2026 | $1.95 | $1.95 | $1.77 | $1.845 | 741.44K |
| Oct 9, 2026 | $1.90 | $1.98 | $1.87 | $1.97 | 435.03K |
| Oct 8, 2026 | $1.94 | $1.94 | $1.86 | $1.91 | 417.26K |
| Oct 7, 2026 | $1.95 | $2.00 | $1.925 | $1.94 | 444.05K |
| Oct 6, 2026 | $1.97 | $2.04 | $1.95 | $1.98 | 583.84K |
| Oct 5, 2026 | $2.00 | $2.025 | $1.955 | $2.00 | 407.49K |
| Oct 2, 2026 | $1.96 | $2.016 | $1.9324 | $2.00 | 434.46K |
The latest Smart Investors Daily articles mentioning IKT.
Company
Market Activity
Research & News
IKT research
Company profile and research snapshot.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Chardan Capital | Neutral | — |
| Jun 10, 2026 | Oppenheimer | Outperform | — |
| Mar 4, 2026 | Ladenburg Thalmann | Buy | — |
| Jan 21, 2026 | B of A Securities | Buy | — |
| Dec 11, 2025 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
ChartMill · Feb 24, 2026
Unusual volume stocks are being observed in Tuesday's session.
Yahoo · Feb 22, 2026
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spending, the margin impact of massive capital expenditures, and whether growth rates can justify the premium multiples many companies still command. That skepticism toward richly valued mega-cap tech has pushed investors to look elsewhere for returns, and biotech ha
Yahoo · Feb 18, 2026
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IKT.
